Patents Assigned to INSTITUT CATALÀ D'ONCOLOGIA (ICO)
  • PD-ECGF as biomarker of cancer
    Patent number: 11802874
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 31, 2023
    Assignees: FUNDACIO INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Oriol Casanovas Casanovas, Gabriela Jiménez Valerio, María Ochoa De Olza, Valentí Navarro Pérez, Nicklas Bassani, Helena Verdaguer
  • Adenovirus comprising an albumin-binding moiety
    Patent number: 11578104
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: February 14, 2023
    Assignees: Fundació Institut D'lnvestigació Biomedica De Bellvitge (í DIBELL), INSTITUT CATALA D'ONCOLOGIA (ICO)
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • Adenovirus comprising an albumin-binding moiety
    Patent number: 10604549
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 31, 2020
    Assignees: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • PD-ECGF AS BIOMARKER OF CANCER
    Publication number: 20180052164
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Application
    Filed: March 10, 2016
    Publication date: February 22, 2018
    Applicants: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Oriol CASANOVAS CASANOVAS, Gabriela JIMÉNEZ VALERIO, María OCHOA DE OLZA, Valentí NAVARRO PÉREZ, Nicklas BASSANI, Helena VERDAGUER